PE20142035A1 - Formulacion compuesta que comprende un comprimido esferoidal de multiples unidades (must) encapsulada en una capsula dura y metodo para preparar la misma - Google Patents
Formulacion compuesta que comprende un comprimido esferoidal de multiples unidades (must) encapsulada en una capsula dura y metodo para preparar la mismaInfo
- Publication number
- PE20142035A1 PE20142035A1 PE2014001632A PE2014001632A PE20142035A1 PE 20142035 A1 PE20142035 A1 PE 20142035A1 PE 2014001632 A PE2014001632 A PE 2014001632A PE 2014001632 A PE2014001632 A PE 2014001632A PE 20142035 A1 PE20142035 A1 PE 20142035A1
- Authority
- PE
- Peru
- Prior art keywords
- hard capsule
- encapsulated
- prepare
- same
- multiple units
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000007902 hard capsule Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000002131 composite material Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 abstract 1
- 239000002083 C09CA01 - Losartan Substances 0.000 abstract 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 abstract 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 abstract 1
- 229960005174 ambroxol Drugs 0.000 abstract 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 abstract 1
- 229960000528 amlodipine Drugs 0.000 abstract 1
- 239000011247 coating layer Substances 0.000 abstract 1
- 229960001508 levocetirizine Drugs 0.000 abstract 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 abstract 1
- 229960004773 losartan Drugs 0.000 abstract 1
- 229960005127 montelukast Drugs 0.000 abstract 1
- 229920006254 polymer film Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA FORMULACION COMPUESTA DE UNA CAPSULA DURA QUE COMPRENDE DOS O MAS COMPUESTOS FARMACEUTICAMENTE ACTIVOS TALES COMO LEVOCETIRIZINA, MONTELUKAST, AMBROXOL, LOSARTAN, AMLODIPINA, ENTRE OTROS, EN DONDE CADA COMPUESTO ACTIVO ESTA CONTENIDO EN UN COMPRIMIDO ESFEROIDAL DE MULTIPLES UNIDADES (MUST) QUE TIENE UN DIAMETRO EN UN RANGO DE 1 A 4mm, Y ESTAN RECUBIERTOS CON UNA CAPA DE RECUBRIMIENTO DE PELICULA DE POLIMERO. DICHA FORMULACION CONTIENE DE 4 A 40 MUSTS ENCAPSULADOS EN LA CAPSULA DURA PERMITIENDO LA CARGA DE UNA DOSIS ELEVADA DE COMPUESTOS ACTIVOS DIFERENTES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120038594A KR101378973B1 (ko) | 2012-04-13 | 2012-04-13 | 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20142035A1 true PE20142035A1 (es) | 2014-12-24 |
Family
ID=49327885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014001632A PE20142035A1 (es) | 2012-04-13 | 2013-04-12 | Formulacion compuesta que comprende un comprimido esferoidal de multiples unidades (must) encapsulada en una capsula dura y metodo para preparar la misma |
Country Status (22)
Country | Link |
---|---|
US (1) | US20150098992A1 (es) |
EP (1) | EP2836207B1 (es) |
JP (1) | JP6129295B2 (es) |
KR (1) | KR101378973B1 (es) |
CN (2) | CN104220050A (es) |
BR (1) | BR112014024964B1 (es) |
CL (1) | CL2014002717A1 (es) |
CO (1) | CO7131367A2 (es) |
ES (1) | ES2778864T3 (es) |
HK (1) | HK1204959A1 (es) |
MX (1) | MX354328B (es) |
MY (1) | MY171703A (es) |
PE (1) | PE20142035A1 (es) |
PH (1) | PH12014502271A1 (es) |
PL (1) | PL2836207T3 (es) |
PT (1) | PT2836207T (es) |
RU (1) | RU2014145557A (es) |
SG (1) | SG11201406298RA (es) |
TW (1) | TWI544936B (es) |
UA (1) | UA116102C2 (es) |
WO (1) | WO2013154390A1 (es) |
ZA (1) | ZA201408285B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101910901B1 (ko) * | 2013-11-29 | 2018-10-24 | 한미약품 주식회사 | 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제 |
EP3209285A1 (en) * | 2014-10-21 | 2017-08-30 | Reckitt Benckiser LLC | Pharmaceutical capsule containing at least two tablets |
WO2017003186A1 (en) * | 2015-06-30 | 2017-01-05 | Hanmi Pharm. Co., Ltd. | Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin |
BE1023011B1 (nl) * | 2015-08-05 | 2016-11-04 | Nordic Specialty Pharma Bvba | Acetylsalicylzuur tablet met onmiddellijke afgifte |
CA3001337C (en) | 2015-10-09 | 2023-12-12 | Reckitt Benckiser Llc | Pharmaceutical formulation |
KR101625344B1 (ko) * | 2015-12-21 | 2016-06-08 | 주식회사 유영제약 | 세레콕시브 및 둘록세틴을 함유하는 약제학적 조성물 |
PL3222279T3 (pl) | 2016-03-21 | 2022-05-09 | Invest Bielany Spółka Z Ograniczoną Odpowiedzialnością | Doustny preparat farmaceutyczny montelukastu i lewocetyryzyny oraz sposób jego wytwarzania |
KR101920996B1 (ko) * | 2017-04-26 | 2018-11-22 | 알보젠코리아 주식회사 | HMG-CoA 환원효소 저해제 및 칼슘채널 차단제를 포함하는 복합제제 |
EA202090166A1 (ru) * | 2017-09-28 | 2020-06-29 | Ханми Фарм. Ко., Лтд. | Фармацевтическая композиция, включающая многокомпонентную таблетку сфероидной формы, содержащую эзомепразол и его фармацевтически приемлемую соль, и способ приготовления такой фармацевтической композиции |
KR102026982B1 (ko) * | 2018-02-02 | 2019-09-30 | 주식회사 씨티씨바이오 | 캡슐 충진 장치 |
EP3949955A4 (en) * | 2019-04-02 | 2023-01-04 | Hanmi Pharm. Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING ESOMEPRAZOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND WITH A DOUBLE RELEASE PROFILE |
KR20210052281A (ko) * | 2019-10-29 | 2021-05-10 | 신에쓰 가가꾸 고교 가부시끼가이샤 | 캡슐 충전용 조성물 및 이것을 사용한 캡슐 제제의 제조 방법 그리고 캡슐 제제 |
US20210275531A1 (en) * | 2020-03-04 | 2021-09-09 | VK Research Associates Inc | Phosphodiesterase-5 inhibitor combinations, methods of making, and methods of use thereof |
WO2021211944A1 (en) | 2020-04-17 | 2021-10-21 | Honeybrains, Llc | Compositions and methods for treating neuropsychiatric disorders |
EP4085903A1 (de) * | 2021-05-07 | 2022-11-09 | Midas Pharma GmbH | Minitablette enthaltend losartan für pädiatrische anwendungen |
CA3229117A1 (en) * | 2021-08-19 | 2023-02-23 | Dorit MIMROD | Method of treating parkinson's disease |
KR20240045586A (ko) | 2022-09-30 | 2024-04-08 | 주식회사 제뉴원사이언스 | 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 포함하는 안정성이 향상된 이층정 정제 및 그의 제조방법 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4773907A (en) * | 1982-12-20 | 1988-09-27 | Alza Corporation | Primary delivery system comprising secondary dosage form |
US5391381A (en) * | 1987-06-25 | 1995-02-21 | Alza Corporation | Dispenser capable of delivering plurality of drug units |
US5260068A (en) * | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
GB9711962D0 (en) * | 1997-06-10 | 1997-08-06 | Reckitt & Colmann Prod Ltd | Therapeutically active compositions |
JP2000128779A (ja) * | 1998-10-20 | 2000-05-09 | Mitsui Chemicals Inc | 薬物放出制御型製剤 |
DE19901683B4 (de) * | 1999-01-18 | 2005-07-21 | Grünenthal GmbH | Analgetikum mit kontrollierter Wirkstofffreisetzung |
CZ2002336A3 (cs) * | 1999-07-30 | 2002-06-12 | Smithkline Beecham Plc | Multikomponentní farmaceutická dávková forma |
WO2003103637A2 (en) * | 2002-01-10 | 2003-12-18 | Ranbaxy Laboratories Limited | Modified release, multiple unit drug delivery systems |
EP1462098B1 (en) * | 2003-03-03 | 2007-07-04 | SPRL Franpharma | Stabilised pharmaceutical composition comprising a non-steroidal anti-inflammatory agent and a prostaglandin |
WO2005048979A2 (en) * | 2003-10-06 | 2005-06-02 | Torrent Pharmaceuticals Limited | Pharmaceutical composition having casing with multiple micro tablets |
US9233075B2 (en) * | 2005-08-09 | 2016-01-12 | Metacure Limited | Satiety |
KR100795419B1 (ko) * | 2006-01-03 | 2008-01-17 | (주)네오메딕스 | 암로디핀 및 아스피린을 함유하는 약학 제제 |
CN101516355A (zh) * | 2006-09-12 | 2009-08-26 | 葛兰素集团有限公司 | 包括多个含有因子Xa抑制剂的微型片剂的药物组合物 |
KR100888131B1 (ko) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
CA2685591A1 (en) * | 2007-05-01 | 2008-11-06 | Sigmoid Pharma Limited | Pharmaceutical nimodipine compositions |
EP2255797A4 (en) * | 2008-02-22 | 2011-09-07 | Hanall Biopharma Co Ltd | COMPOSITE PREPARATION |
KR101207618B1 (ko) * | 2008-02-22 | 2012-12-04 | 한올바이오파마주식회사 | 심혈관계 질환 치료용 약제학적 제제 |
KR20110007602A (ko) * | 2008-03-28 | 2011-01-24 | 페레르 인터내쇼날 에스.에이. | 심장혈관계 질병 예방용 캡슐 |
TR201005325A2 (tr) * | 2010-06-30 | 2012-01-23 | Bi̇lgi̇ç Mahmut | Atorvastatin ve aspirin içeren farmasötik formülasyonlar |
KR101298788B1 (ko) * | 2011-03-15 | 2013-08-22 | 보령제약 주식회사 | 안정성이 개선된 복합제제 |
-
2012
- 2012-04-13 KR KR1020120038594A patent/KR101378973B1/ko active IP Right Grant
-
2013
- 2013-04-12 UA UAA201412220A patent/UA116102C2/uk unknown
- 2013-04-12 RU RU2014145557A patent/RU2014145557A/ru unknown
- 2013-04-12 EP EP13775814.0A patent/EP2836207B1/en active Active
- 2013-04-12 MY MYPI2014702956A patent/MY171703A/en unknown
- 2013-04-12 PT PT137758140T patent/PT2836207T/pt unknown
- 2013-04-12 US US14/391,111 patent/US20150098992A1/en not_active Abandoned
- 2013-04-12 CN CN201380019865.6A patent/CN104220050A/zh active Pending
- 2013-04-12 PL PL13775814T patent/PL2836207T3/pl unknown
- 2013-04-12 SG SG11201406298RA patent/SG11201406298RA/en unknown
- 2013-04-12 CN CN201910062530.1A patent/CN110051642B/zh active Active
- 2013-04-12 BR BR112014024964-4A patent/BR112014024964B1/pt active IP Right Grant
- 2013-04-12 WO PCT/KR2013/003099 patent/WO2013154390A1/en active Application Filing
- 2013-04-12 TW TW102113097A patent/TWI544936B/zh not_active IP Right Cessation
- 2013-04-12 PE PE2014001632A patent/PE20142035A1/es not_active Application Discontinuation
- 2013-04-12 ES ES13775814T patent/ES2778864T3/es active Active
- 2013-04-12 JP JP2015505646A patent/JP6129295B2/ja not_active Expired - Fee Related
- 2013-04-12 MX MX2014012144A patent/MX354328B/es active IP Right Grant
-
2014
- 2014-10-08 PH PH12014502271A patent/PH12014502271A1/en unknown
- 2014-10-09 CL CL2014002717A patent/CL2014002717A1/es unknown
- 2014-11-10 CO CO14247711A patent/CO7131367A2/es unknown
- 2014-11-12 ZA ZA2014/08285A patent/ZA201408285B/en unknown
-
2015
- 2015-06-16 HK HK15105701.2A patent/HK1204959A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BR112014024964A2 (pt) | 2017-06-20 |
EP2836207B1 (en) | 2020-02-19 |
PH12014502271B1 (en) | 2014-12-10 |
BR112014024964A8 (pt) | 2021-06-15 |
BR112014024964B1 (pt) | 2022-03-15 |
SG11201406298RA (en) | 2014-11-27 |
JP6129295B2 (ja) | 2017-05-17 |
CN104220050A (zh) | 2014-12-17 |
PT2836207T (pt) | 2020-03-26 |
PH12014502271A1 (en) | 2014-12-10 |
UA116102C2 (uk) | 2018-02-12 |
MY171703A (en) | 2019-10-23 |
CN110051642A (zh) | 2019-07-26 |
MX2014012144A (es) | 2014-12-05 |
KR101378973B1 (ko) | 2014-03-28 |
TWI544936B (zh) | 2016-08-11 |
HK1204959A1 (en) | 2015-12-11 |
WO2013154390A1 (en) | 2013-10-17 |
TW201345568A (zh) | 2013-11-16 |
MX354328B (es) | 2018-02-27 |
CN110051642B (zh) | 2021-12-31 |
CL2014002717A1 (es) | 2015-01-09 |
JP2015517998A (ja) | 2015-06-25 |
EP2836207A4 (en) | 2015-08-19 |
EP2836207A1 (en) | 2015-02-18 |
ES2778864T3 (es) | 2020-08-12 |
US20150098992A1 (en) | 2015-04-09 |
ZA201408285B (en) | 2016-09-28 |
RU2014145557A (ru) | 2016-06-10 |
PL2836207T3 (pl) | 2020-07-27 |
CO7131367A2 (es) | 2014-12-01 |
KR20130115864A (ko) | 2013-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20142035A1 (es) | Formulacion compuesta que comprende un comprimido esferoidal de multiples unidades (must) encapsulada en una capsula dura y metodo para preparar la misma | |
EA201591821A1 (ru) | Защищенные от несанкционированного использования фармацевтические составы | |
BR112013029422A2 (pt) | cápsulas núcleo-revestimento | |
BR112015023515A8 (pt) | construtos de tecido hepático tridimensionais vivos engenheirados, métodos para fabricá-los e uso destes para aumentar uma ou mais funções hepáticas em um ser humano | |
CO2017003070A2 (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos | |
CO2018013747A2 (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos | |
CR20140365A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
EA201591403A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
WO2014170389A8 (en) | Enhanced adoptive cell therapy | |
NI201600037A (es) | Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso. | |
WO2014205389A8 (en) | Nuclear transport modulators and uses thereof | |
BR112015009189A2 (pt) | conjunto de potência para um autoinjetor e autoinjetor que contém o mesmo | |
UA111834C2 (uk) | Лікарська форма | |
BR112013006395A2 (pt) | moduladores do receptor de estrogênio e seus usos. | |
PE20150223A1 (es) | Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos | |
CR20140487A (es) | Peliculas de capas multiples capaces de liberar ingredientes activos por un periodo limitado de tiempo | |
BR112012025015A2 (pt) | formulações farmacêuticas para tratamento de bexiga hiperativa. | |
CL2013001979A1 (es) | Composicion farmaceutica en tableta, que comprende compuestos inmunosupresores, moduladores del receptor s1p, que incluye tambien un desecante y se recubre con una barrera a la humedad. | |
UA112540C2 (uk) | Плівкова лікарська форма, яка містить вільну основу силденафілу, і спосіб її отримання | |
BR112012028090A2 (pt) | comprimidos de meloxicam de baixa concentração | |
EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
PH12015502093A1 (en) | Antiemetic extended release solid dosage forms | |
BR112014031706A8 (pt) | Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol | |
BR112015020820A2 (pt) | formulação farmacêutica que contém glicosaminoglicano |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |